Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering

NEXT STORY
CorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference
PREV STORY
XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress

Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ ...

author_avatar
NASDAQ Market News

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

BURLINGAME, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage ...

author_avatar
NASDAQ Market News

Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at ESMO Congress 2017

Acceptable tolerability observed in first-in-human study Encouraging initial anti-leukemic activity observed in relapsed/refractory AML ...

author_avatar
NASDAQ Market News